Cellosaurus logo
expasy logo

Cellosaurus Ma-Mel-30 (CVCL_A165)

[Text version]
Cell line name Ma-Mel-30
Synonyms Ma-Mel_30; Ma-Mel 30; MaMel-30; MaMel30
Accession CVCL_A165
Resource Identification Initiative To cite this cell line use: Ma-Mel-30 (RRID:CVCL_A165)
Comments Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
Sequence variations
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,26:12
HLA-BB*57:01
HLA-CC*06:02
Class II
HLA-DPDPB1*04:01,03:01
HLA-DQDQB1*03:03:02
HLA-DRDRB1*07:01
Disease Acral lentiginous melanoma (NCIt: C4022)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 58Y
Category Cancer cell line
STR profile Source(s): ESTDAB=ESTDAB-104

Markers:
AmelogeninX,Y
CSF1PO12,13
D3S135816
D5S81812,13
D7S82011
D13S31710,11
FGA21,23.2
TH019.3
TPOX8,11
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A., Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595
Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A., Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R., Schadendorf D.
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
PLoS ONE 2:E236-E236(2007)

PubMed=20544847; DOI=10.1002/gcc.20785
Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A., Hemminki K., Schadendorf D., Kumar R.
Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.
Genes Chromosomes Cancer 49:733-745(2010)

PubMed=23348503; DOI=10.1126/science.1230062
Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.
TERT promoter mutations in familial and sporadic melanoma.
Science 339:959-961(2013)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330
Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A., Hemminki K., Schadendorf D., Kumar R.
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.
Oncotarget 7:16490-16504(2016)

Cross-references
Cell line databases/resources cancercelllines; CVCL_A165
ESTDAB; ESTDAB-104
Encyclopedic resources Wikidata; Q54903783
Gene expression databases GEO; GSM109060
GEO; GSM437000
Polymorphism and mutation databases Cosmic; 1467749
Cosmic; 2163817
Cosmic; 2686392
Progenetix; CVCL_A165
Entry history
Entry creation06-Jun-2012
Last entry update19-Dec-2024
Version number21